Trial Profile
A Phase I Dose Escalation Study of Darinaparsin in Combination With CHOP in Previously Untreated Patients With Lymphomas Who Are Scheduled to Receive CHOP Alone.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Darinaparsin (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; Vincristine (Primary)
- Indications B-cell lymphoma; Hodgkin's disease; Non-Hodgkin's lymphoma; T-cell lymphoma
- Focus Adverse reactions
- Sponsors Alaunos Therapeutics
- 26 May 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 13 Oct 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 09 Jun 2010 New trial record